Home Featured Page 292

Featured

Latest

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital...

Nova Mentis Establishes Serotonin Research Centre

Psyence Group and Pure Extracts Sign JV Letter of Intent for...

MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with...

Noetic Launches Venture Studio to Build Psychedelic Biotechnology Companies

Lemon Tek to the Rescue for Magic Mushroom Nausea?

Cybin Announces Senior Management Changes to Lead Buildout of Development and...

AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD

PT237 – Dena Justice – Finding the Frequency of Safety

EDITOR PICKS

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital...

Nova Mentis Establishes Serotonin Research Centre

Psyence Group and Pure Extracts Sign JV Letter of Intent for...

MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with...

Noetic Launches Venture Studio to Build Psychedelic Biotechnology Companies

Lemon Tek to the Rescue for Magic Mushroom Nausea?

Cybin Announces Senior Management Changes to Lead Buildout of Development and...

AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD

PT237 – Dena Justice – Finding the Frequency of Safety

EDITOR PICKS

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY